Modified antisense oligomers for exon inclusion in spinal muscular atrophy
The present disclosure relates to modified antisense oligomers and related compositions and methods for increasing the expression of functional SMN protein and methods for treating spinal muscular atrophy and relates to inducing inclusion of exon 7 in SMN2 mRNA.
1. A compound of formula (VII):
or a pharmaceutically acceptable salt thereof, wherein:
each Nu is a nucleobase which taken together form a targeting sequence;
Z is an integer from 6 to 38;
T is a moiety of the formula:
each R 1 is independently selected from:
R 2 is selected from H, acyl, trityl, 4-methoxytrityl, and C 1 -C 6 alkyl,
wherein at least one R 1 is:
and wherein the targeting sequence: (a) comprises a sequence selected from SEQ ID NOS: 35-37, (b) is selected from SEQ ID NOS: 35-37, or (c) is a fragment of at least 8 contiguous nucleotides of a targeting sequence selected from SEQ ID NOS: 35-37.
2. The compound of claim 1 , wherein at least one R 1 is
3. The compound of claim 1 , wherein T is:
4. The compound of claim 1 , wherein R 2 is H.
5. The compound of claim 1 , wherein at least one R 1 is
T is:
6. The compound of claim 1 , wherein T is:
and R 2 is H.
7. The compound of claim 1 , wherein each R 1 is independently selected from
T is:
and R 2 is H, wherein at least one R 1 is
8. The compound of claim 1 , wherein the compound is a compound of formula (VIIa):
or a pharmaceutically acceptable salt thereof, where:
each Nu is a nucleobase which taken together form a targeting sequence;
Z is an integer from 6 to 38; and
each R 1 is independently selected from:
wherein at least one R 1 is:
9. The compound of claim 1 , wherein Z is an integer from 16 to 23.
10. The compound of claim 1 , wherein the targeting sequence is SEQ ID NO: 35.
11. The compound of claim 1 , wherein the targeting sequence is SEQ ID NO: 36.
12. The compound of claim 1 , wherein the targeting sequence is SEQ ID NO: 37.
13. The compound of claim 1 , wherein the compound is PMO-APN-9, PMO-APN-10, PMO-APN-11, PMO-APN-12, PMO-APN-13, PMO-APN-14, PMO-APN-15, PMO-APN-16, or PMO-APN-17.
14. The compound of claim 1 , wherein the compound is PMO-APN-11 or PMO-APN-16.
15. A pharmaceutical composition comprising a compound of formula (VII):
or a pharmaceutically acceptable salt thereof, wherein:
each Nu is a nucleobase which taken together form a targeting sequence;
Z is an integer from 6 to 38;
T is a moiety of the formula:
each R 1 is independently selected from
R 2 is selected from H, acyl, trityl, 4-methoxytrityl, and C 1 -C 6 alkyl,
wherein at least one R 1 is:
and wherein the targeting sequence: (a) comprises a sequence selected from SEQ ID NOS: 35-37, (b) is selected from SEQ ID NOS: 35-37, or (c) is a fragment of at least 8 contiguous nucleotides of a targeting sequence selected from SEQ ID NOS: 35-37.
16. A method of treating spinal muscular atrophy (SMA) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (VII):
or a pharmaceutically acceptable salt thereof, wherein:
each Nu is a nucleobase which taken together form a targeting sequence;
Z is an integer from 6 to 38;
T is a moiety of the formula:
each R 1 is independently selected from:
R 2 is selected from H, acyl, trityl, 4-methoxytrityl, and C 1 -C 6 alkyl,
wherein at least one R 1 is:
and wherein the targeting sequence: (a) comprises a sequence selected from SEQ ID NOS: 35-37, (b) is selected from SEQ ID NOS: 35-37, or (c) is a fragment of at least 8 contiguous nucleotides of a targeting sequence selected from SEQ ID NOS: 35-37.